Biofrontera第三季产品收入910万美元增29.8%：毛利率74.4%、净亏损640万美元，11月13日发布
皮肤科光动力疗法公司Biofrontera Inc.于2026年11月13日经GlobeNewswire公布截至2026年9月30日的第三季业绩。以下数字均出自公司业绩稿正文，稿件不作投资建议。
第三季净产品收入为910万美元，较上年同期的700万美元增加210万美元、增幅29.8%。
收入成本为230万美元，上年同期为200万美元，毛利为670万美元，毛利率为74.4%，上年同期毛利为490万美元、毛利率为70.7%，改善约370个基点。公司称这反映2025年10月与Biofrontera AG战略交易交割后建立的较低Ameluz成本结构，部分被与ITC事项相关的存货减记及更高的灯具与设备成本抵消。
第三季净亏损为640万美元、每股亏损0.42美元，上年同期净亏损为660万美元、每股亏损0.62美元。调整后EBITDA亏损为550万美元，上年同期为600万美元。
业务方面，公司称Ameluz于2026年9月9日获美国食品药品管理局批准用于治疗浅表型基底细胞癌，使Ameluz加红光成为首个且唯一获批治疗癌性皮肤肿瘤的光动力疗法。公司于11月13日美东时间上午10时举行电话会与网络直播。
Biofrontera Third-Quarter Product Revenue of 9.1 Million Dollars Rises 29.8 Percent: A Gross Margin of 74.4 Percent and a Net Loss of 6.4 Million Dollars, Released November 13
Biofrontera Inc., which specializes in the development and commercialization of photodynamic therapy in dermatology, reported financial results for the quarter ended September 30, 2026 through GlobeNewswire on November 13, 2026. All figures below are from the body of the company's results release, and this report offers no investment advice.
Third-quarter net product revenue was 9.1 million dollars, an increase of 2.1 million dollars, or 29.8 percent, from 7.0 million dollars in the third quarter of 2025.
Cost of revenues was 2.3 million dollars, against 2.0 million dollars, producing gross profit of 6.7 million dollars and a gross margin of 74.4 percent, compared with gross profit of 4.9 million dollars and a gross margin of 70.7 percent in the prior-year quarter, an improvement of approximately 370 basis points. The company attributed this to the lower Ameluz cost structure established following the closing of the strategic transaction with Biofrontera AG in October 2025, partially offset by ITC matter-related inventory write-downs and higher lamp and device costs.
The net loss for the third quarter was 6.4 million dollars, or 0.42 dollars per share, compared with a net loss of 6.6 million dollars, or 0.62 dollars per share, in the prior-year quarter. Adjusted EBITDA was a loss of 5.5 million dollars, compared with a loss of 6.0 million dollars.
On September 9, 2026, Ameluz received FDA approval for the treatment of superficial basal cell carcinoma, making Ameluz plus red light the first and only photodynamic therapy approved for the treatment of cancerous skin tumors, the company said. Biofrontera hosted a conference call and webcast on November 13, 2026 at 10:00 a.m. Eastern time.
来源：Biofrontera
发布：GSM·美国（发布链接）
图片来源：图：Biofrontera Inc相关图(资料图)。作者与授权：Biofrontera AG，CC BY-SA 4.0，维基共享资源。 / Photo: Image related to Biofrontera Inc (file photo). Credit: Biofrontera AG, CC BY-SA 4.0, Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
